Hungarian nuclear medicine supplier Medi-Radiopharma is launching an R&D investment to develop a pioneering manufacturing technology, the Hungarian Investment Promotion Agency (HIPA) reports.
Supported by the HIPA, the EUR 6.56 million investment aims to introduce an industry-scale, automated technology to produce radiopharmaceuticals, that is faster, and more efficient and accurate than the currently dominant manual, small-dose method.
The project is expected to create 30 new jobs, most of them for highly qualified professionals in R&D and advanced technology fields. The new technology could set a new industry standard and strengthen Hungary’s position as a regional hub in nuclear medicine. According to information from the Hungarian Ministry of Foreign Affairs and Trade, the state subsidy for this investment is 30%.
Radiopharmaceuticals are primarily used in diagnostics. The radioactive preparations allow for the examination of various organs, assisting doctors in identifying malignant conditions and monitoring effects of treatments.
Medi-Radiopharma was founded in 1995 and has contributed to tens of millions of diagnostic procedures worldwide. The company employs around 100 people, generates more than 90 percent of its revenue from exports, and sells its products in over 80 countries.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Genius Automotive Hungarian Subsidiary's CEE Expansion November 2, 2025 
Asiana Airlines to Launch Direct Seoul-Budapest Flight October 31, 2025
